Inhibition of human cytochrome P450 2D6 (CYP2D6) by methadone.
about
Methadone N-demethylation in human liver microsomes: lack of stereoselectivity and involvement of CYP3A4Variability in metabolism of imipramine and desipramine using urinary excretion data.Development of a rapid and sensitive high-performance liquid chromatographic method to determine CYP2D6 phenotype in human liver microsomes.Summary of information on human CYP enzymes: human P450 metabolism data.The physiological and pharmacological roles of cytochrome P450 isoenzymes.Contribution of cytochrome P450 and ABCB1 genetic variability on methadone pharmacokinetics, dose requirements, and responseThe role of CYP2D6 in primary and secondary oxidative metabolism of dextromethorphan: in vitro studies using human liver microsomesInteractions between recreational drugs and antiretroviral agents.The role of methadone in cancer pain treatment--a review.Efflux transporters- and cytochrome P-450-mediated interactions between drugs of abuse and antiretrovirals.Opioids: a review.Gender differences in pharmacokinetics and pharmacodynamics of methadone substitution therapyA discordance between cytochrome P450 2D6 genotype and phenotype in patients undergoing methadone maintenance treatment.Clinical inhibition of CYP2D6-catalysed metabolism by the antianginal agent perhexiline.Subjective and physiological responses among racemic-methadone maintenance patients in relation to relative (S)- vs. (R)-methadone exposure.Differential in vitro inhibition of M3G and M6G formation from morphine by (R)- and (S)-methadone and structurally related opioids.Methadone inhibits CYP2D6 and UGT2B7/2B4 in vivo: a study using codeine in methadone- and buprenorphine-maintained subjects.Pharmacogenetics of drug-drug interaction and drug-drug-gene interaction: a systematic review on CYP2C9, CYP2C19 and CYP2D6.Inhibition of CYP2D6-mediated tramadol O-demethylation in methadone but not buprenorphine maintenance patients.Pharmacogenetics of analgesics: toward the individualization of prescription.Benzodiazepines, methadone and buprenorphine: interactions and clinical management.Methadone: a review of drug-drug and pathophysiological interactions.Metabolomics of methadone: clinical and forensic toxicological implications and variability of dose response.Interpatient variability: genetic predisposition and other genetic factors.Pharmacokinetic interaction between voriconazole and methadone at steady state in patients on methadone therapy.Effect of ritonavir-boosted danoprevir, a potent hepatitis C virus protease inhibitor, on the pharmacokinetics of methadone in healthy subjects undergoing methadone maintenance therapy.Polymorphism of human cytochrome P450 2D6 and its clinical significance: part II.Role of CYP3A5 in abnormal clearance of methadone.Methadone as a "Tumor Theralgesic" against Cancer.P450 Pharmacogenetics in Indigenous North American Populations.An in vitro approach to potential methadone metabolic-inhibition interactions.In vitro assessment of 24 CYP2D6 allelic isoforms on the metabolism of methadone.
P2860
Q24564971-FD664321-FDC5-4C9A-9E2B-8DBECD06838AQ30811482-749A2859-5500-4122-900D-8BE75636E909Q31036625-83823FE8-E75A-4056-AA54-4AFAA333FA0FQ32103802-979C7417-EC64-4F1D-8CA8-3A44B0B15066Q33597477-8E3728A5-EFBE-4872-B471-790CCF4A7557Q33903933-2D1E1833-A011-45CB-909C-2C5059CA10CBQ34346292-3AC38853-DA3B-4FD2-BDC3-973804EA9A7CQ34874414-EDC611F0-8F72-48D5-9583-89DE35594BF9Q34990113-F351F8B8-0475-46B3-97A7-D879AAF27D0CQ35000765-4A9BE51A-CB51-4C9A-8033-662B338F5817Q35044015-1D79E5AD-7B7A-4CA2-A491-B72C708369BFQ35698405-FD335B58-1E95-4512-A7C4-A0C751853FCFQ35825489-19D55595-B2F3-4266-88E0-37A5B7B08D32Q35826004-E4199F36-3168-4BB1-9D41-44CCFEC87291Q35826518-680DD096-2C88-4D66-8AC1-DA3664639AB8Q35827481-EDC4EEF5-1579-427D-9A1E-5DC642B6F8B1Q36111225-DB226DB5-6D1C-4EE1-8446-1F6B906F2D47Q36365500-DACCE3EC-5D50-4A1C-AADC-8D94363A1441Q36390262-112E88ED-B6CD-4F2A-83FA-EFB99DCAAAE0Q37205954-2C2114F8-855E-4B8D-9491-7FBB4ABE6D60Q37687450-7F4D80B5-82B8-4DEC-8FF5-34873FDE9202Q37950478-638C1298-B8B8-43F2-A05C-9D217BCBE999Q38870014-7E9DE74B-ED8E-4AF9-A57F-BDA0FCCDC46EQ41550904-B8797ADE-0A01-4AC9-915E-0E24F539891EQ42272330-DDD97D22-A908-4842-B0A1-2C344095BCACQ42276687-0279DB3E-DF93-4D7B-80FA-8E12B52FC37DQ43244977-73AF53B1-E9B5-40EE-9B66-F6140D63A2C5Q46609377-626E8A33-D20A-4E09-850E-6A1B2582D516Q47150971-87643DE9-FB01-468B-8A3D-A9D1BF1AC7ECQ47546933-2EC28D09-064E-49E9-AEB5-1F9397D73B4CQ51911686-C9B98BDB-2046-46A0-A31F-3E4CEBFF726AQ52845121-277D26C7-B3FB-4F20-B8AD-334A45EBAC16
P2860
Inhibition of human cytochrome P450 2D6 (CYP2D6) by methadone.
description
1993 nî lūn-bûn
@nan
1993 թուականի Յունուարին հրատարակուած գիտական յօդուած
@hyw
1993 թվականի հունվարին հրատարակված գիտական հոդված
@hy
1993年の論文
@ja
1993年論文
@yue
1993年論文
@zh-hant
1993年論文
@zh-hk
1993年論文
@zh-mo
1993年論文
@zh-tw
1993年论文
@wuu
name
Inhibition of human cytochrome P450 2D6 (CYP2D6) by methadone.
@ast
Inhibition of human cytochrome P450 2D6 (CYP2D6) by methadone.
@en
Inhibition of human cytochrome P450 2D6
@nl
type
label
Inhibition of human cytochrome P450 2D6 (CYP2D6) by methadone.
@ast
Inhibition of human cytochrome P450 2D6 (CYP2D6) by methadone.
@en
Inhibition of human cytochrome P450 2D6
@nl
prefLabel
Inhibition of human cytochrome P450 2D6 (CYP2D6) by methadone.
@ast
Inhibition of human cytochrome P450 2D6 (CYP2D6) by methadone.
@en
Inhibition of human cytochrome P450 2D6
@nl
P2093
P2860
P1476
Inhibition of human cytochrome P450 2D6 (CYP2D6) by methadone.
@en
P2093
Sellers EM
Sproule BA
P2860
P356
10.1111/J.1365-2125.1993.TB05666.X
P407
P577
1993-01-01T00:00:00Z